Sareum Restarts Key Toxicology Study as TYK2 Pipeline and Partnering Drive Half-Year Progress

The latest announcement is out from Sareum Holdings ( (GB:SAR) ).

Sareum Holdings reported half-year results to 31 December 2025, underscoring progress on its pipeline of kinase inhibitors for autoimmune disease, cancer and neuroinflammation, while ending the period with £2.5 million in cash and a reduced pre-tax loss of £1.9 million. The company is advancing its TYK2/JAK1 portfolio with limited resources, positioning itself through targeted R&D and business development to secure future partnerships and non-dilutive funding.

Operationally, Sareum restarted the Phase 2-enabling toxicology programme for lead psoriasis candidate SDC-1801 after confirming prior control-group safety findings were unrelated to the drug, and expects dosing to finish by mid-2026 with a Phase 2-ready package by year-end. Formulation optimisation to enable higher doses and fewer capsules is nearing completion, and the full Phase 1 dataset has been submitted for peer review, reinforcing management’s view of SDC-1801 as a differentiated, once-daily oral therapy in a competitive autoimmune field.

In oncology, translational work on SDC-1802 has been completed, showing strongest responses in niche, high-unmet-need cancers and prompting Sareum to seek a development partner for further progress. For SRA737, the company continues active partnering discussions supported by positive Phase 1/2 data in anogenital cancers, strengthened economics with a 63.5% revenue share, an active U.S. IND for blood cancers, and extended patent protection on the crystal form to at least 2041.

Sareum is also expanding into neuroinflammatory indications via a collaboration with Receptor.AI to design blood-brain barrier-penetrant TYK2/JAK1 inhibitors, with initial compound batches already synthesised and tested in early assays. To accelerate deal-making across its lead assets, Sareum has engaged a specialist U.S.-based business development consultancy, which management says is already beginning to broaden and speed up partnering discussions, potentially altering the company’s funding mix and risk profile over the medium term.

The most recent analyst rating on (GB:SAR) stock is a Sell with a £13.50 price target. To see the full list of analyst forecasts on Sareum Holdings stock, see the GB:SAR Stock Forecast page.

Spark’s Take on GB:SAR Stock

According to Spark, TipRanks’ AI Analyst, GB:SAR is a Neutral.

The score is primarily constrained by weak financial performance (pre-revenue with persistent losses and continued cash burn) and bearish technical signals (below key moving averages with negative MACD). Valuation provides limited support because the company is loss-making and no dividend yield is available.

To see Spark’s full report on GB:SAR stock, click here.

More about Sareum Holdings

Sareum Holdings, based in Cambridge and listed on AIM, is a clinical-stage biotechnology company developing next-generation small-molecule kinase inhibitors targeting the JAK family for autoimmune diseases and cancer. Its lead asset, SDC-1801, is a dual TYK2/JAK1 inhibitor for autoimmune conditions such as psoriasis, alongside oncology candidate SDC-1802 and checkpoint kinase 1 inhibitor SRA737, plus an emerging TYK2 neuroscience programme for neuroinflammatory disorders.

Average Trading Volume: 229,509

Technical Sentiment Signal: Strong Sell

Current Market Cap: £19.33M

For a thorough assessment of SAR stock, go to TipRanks’ Stock Analysis page.